
People taking compounded versions of Ozempic have been overdosing on the drug, the U.S. Food and Drug Administration warns. These ODs typically are due to miscommunications or miscalculations regarding dosage, the FDA added. “Dosing errors have resulted from patients measuring and self-administering incorrect doses of the drug and health care providers miscalculating doses of the drug,” the FDA alert said. Health problems caused by overdoses of compounded semaglutide — the main ingredient in Ozempic and Wegovy — include severe nausea, vomiting and hypoglycemia, the FDA said. Other side effects include fainting, headache, migraine, dehydration, pancreatitis and gallstones. People who have a severe overdose might need to be kept for observation for an extended period, since the half-life of semaglutide is about a week, the FDA said. Drug compounding involves combining, mixing or altering drugs to create a medication tailored to the needs of an individual patient. “FDA is aware of compounded semaglutide products that are being marketed for weight loss,” the agency said. “Compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, quality or effectiveness.” “Compounded drugs should only be used for patients whose medical needs cannot be met by an available FDA-approved drug,” the agency added. Compounded semaglutide products can come in varying concentrations, and often are provided in multiple-use vials… read on > read on >